PMcardio receives FDA Breakthrough Device Designation — read the full story
Powerful Medical
30. May 2022

We have successfully received the CE-mark for PMcardio under the EU Medical Device Regulation!

PMcardio is an AI-powered clinical assistant supporting clinicians in diagnosing and managing over 40 cardiovascular diseases. The platform is available as a user-friendly smartphone application, making it accessible to all hospital staff and primary care practitioners. The platform can be neatly incorporated into hospital and practice systems, driving clinical decisions and providing recommendations based on the latest clinical guidelines. Empowering healthcare professionals in tackling the number one cause of death globally, PMcardio can save lives and significantly reduce healthcare costs.

With the introduction of the EU MDR in summer last year in place of the EU Medical Device Directive (MDD), the medical device industry has been shaken up with stricter and neck-breaking regulations and conformity assessments – especially for medical device software.

Challenged by this change, we navigated through the complex certification process by automating most regulatory processes, concepts, and day-to-day workflows.

“We have automated many of the key regulatory processes, concepts, and day-to-day workflows, enforcing compliance across the board,” comments Simon Rovder, CTO at Powerful Medical. “At Powerful Medical, we don’t look for any solution. We don’t stop until we find the solution,” he continues.

Due to the transition from the MDD to the MDR, only a few notified bodies are still accredited to certify medical devices, which presents an additional challenge for medical device companies and startups. With all companies having to recertify due to the regulation change, the notified bodies are overwhelmed, further delaying certification times.

A recent survey from the renowned German medical device consultancy Johner Institute has demonstrated that the average time from successful audits to released certificates has increased from 1-3 months to 6-12 months, with some manufacturers waiting for over 18 months already.

Therefore, with the globally known and recognized Notified Body TÜV SÜD from Germany, we chose a strong and international partner for the entirety of Europe, including the United Kingdom which, after Brexit, requires the UKCA mark starting summer 2023.

An image of an emergency medical professional scanning an ECG with their phone via the PMcardio app
The accurate diagnosis of heart attacks in emergency care is one of PMcardio’s many use-cases!

“We’re a European company, and Europe is our key market. Having successfully obtained the CE-marking in the EU under the new regulation allows us to market the world’s first AI-powered platform for ECG Digitization, Interpretation, and Patient Management across Europe. Being certified as a class II(b) medical device allows PMcardio to not only inform decision-making but actually drive it, making it a powerful tool in the healthcare professionals’ pocket”, comments Martin Herman, CEO at Powerful Medical.

Looking at the competition, the EU Medical Device Regulation has forced many European medical device companies, especially startups, to abandon or delay their EU certification plans and pursue the US FDA approval, which, since the recent regulation change, is considerably easier to obtain than the CE-mark under the EU MDR.

“With the EU CE-mark in our pocket, we can now feel confident about the US FDA approval. Already in the process, we’re expecting the US FDA approval of our first product later this year”, comments Martin Herman.

In line with the expected FDA approval, we’re now preparing for a large Series A with US Healthcare Investors to expand our commercialization efforts beyond Europe.

Powerful Medical

Powerful Medical leads one of the most important shifts in modern medicine by augmenting human-made clinical decisions with artificial intelligence. Our primary focus is on cardiovascular diseases, the world’s leading cause of death.
Powerful Medical leads one of the most important shifts in modern medicine by augmenting human-made clinical decisions with artificial intelligence. Our primary focus is on cardiovascular diseases, the world’s leading cause of death.
About PMcardio:

PMcardio is the market leader in AI-powered diagnostics, addressing the world’s leading cause of death – cardiovascular diseases. The innovative clinical assistant empowers healthcare professionals to detect up to 40 cardiovascular diseases. In the form of a smartphone application, the certified Class IIb medical device interprets any 12-lead ECG image in under 5 seconds to provide accurate diagnoses and individualized treatment recommendations tailored to each patient.

About Powerful Medical:

Established in 2017, Powerful Medical has embarked on a mission to revolutionize the diagnosis and treatment of cardiovascular diseases. We are a medical company backed by 28 world-class cardiologists and led by our expert Scientific Board with decades of experience in daily patient care, clinical research, and medical devices. The results of our research are implemented, developed, certified, and brought to market by our 50+ strong interdisciplinary team of physicians, data scientists, AI experts, software engineers, regulatory specialists, and commercial teams.

Share this article

Don't miss these

ECG Interpretation Tools Compared – Why PMcardio Stands Out

Interpreting ECGs accurately and swiftly is essential for clinicians at every frontline patient encounter—from primary care to emergency settings. Choosing the appropriate interpretation tool significantly impacts patient outcomes. Today, we explore three accessible solutions for clinicians: Conventional ECG Algorithms, General AI language models like ChatGPT, and PMcardio.

Powerful Medical Receives FDA Breakthrough Device Designation for PMcardio STEMI AI ECG Model

Powerful Medical, a leader in AI-driven cardiovascular diagnostics, announces that its PMcardio STEMI AI ECG model has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). This designation recognizes PMcardio as a breakthrough technology for the detection of ST-elevation myocardial infarction (STEMI) and STEMI equivalents—a life-threatening cardiac condition requiring immediate intervention.

Join over 100,000 healthcare professionals who are already taking advantage of AI